Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SRN 101 - Siren Biotechnology

Next Previous
Drug Profile

SRN 101 - Siren Biotechnology

Alternative Names: SRN-101 - Siren Biotechnology

Latest Information Update: 15 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Siren Biotechnology
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Interferon replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioma; Solid tumours

Most Recent Events

  • 14 Oct 2026 Siren Biotechnology plans a phase I trial for Glioma (Second-line therapy or greater) in USA (Intratumoral) (NCT07826949)
  • 26 Jun 2026 Siren Biotechnology plans a phase I/II trial for Glioma (Recurrent, Late-stage disease) in USA
  • 23 Mar 2026 US FDA approves an IND application submitted by the University of California, San Francisco to initiate a phase I/II study for SRN 101 in Glioma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top